Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics

Mydecine Innovations Group Inc. and Johns Hopkins University said on 18 August that they will undertake a five-year collaboration to study the use of psychedelic compounds in smoking cessation and other applications, expanding an existing relationship. The partnership will build upon work done by the university’s behavioral pharmacology research unit investigating the therapeutic use of psychedelics.

Mydecine executives said expanding the research alliance beyond smoking cessation will enable exploration of numerous other projects over the next five years, looking at multiple mushroom-derived molecules and medications in...